Back to People Listing
Affiliate Faculty

Guido Ferrari

Assistant Professor, Surgery
School of Medicine
(919) 684-2862
Guido Ferrari

Summary

Dr. Ferrari is currently an Associate Research Professor in the Department of Surgery, Division of Surgical Sciences at Duke University Medical Center. He is directing the ELISPOT, CTL, and ADCC laboratories for the HVTN central laboratory at Duke. He has been serving as a WHO/UNAIDS Vaccine Initiative consultant for the past six years, and coordinated the organization of 5 international workshops for the transfer of ELISpot and ICS technologies to new laboratory sites involved in HIV vaccine studies.

Locations

Projects

Recent Publications

Saunders, KO, Santra, S, Parks, R, Yates, NL, Sutherland, LL, Scearce, RM, Balachandran, H, Bradley, T, Goodman, D, Eaton, A, Stanfield-Oakley, SA, Tartaglia, J, Phogat, S, Pantaleo, G, Esteban, M, Gomez, CE, Perdiguero, B, Jacobs, B, Kibler, K, Korber, B, Montefiori, DC, Ferrari, G, Vandergrift, N, Liao, H-X, Tomaras, GD, & Haynes, BF. (2018, April). Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. Journal of virology, 92 (8).
Fong, Y, Shen, X, Ashley, VC, Deal, A, Seaton, KE, Yu, C, Grant, SP, Ferrari, G, deCamp, AC, Bailer, RT, Koup, RA, Montefiori, D, Haynes, BF, Sarzotti-Kelsoe, M, Graham, BS, Carpp, LN, Hammer, SM, Sobieszczyk, M, Karuna, S, Swann, E, DeJesus, E, Mulligan, M, Frank, I, Buchbinder, S, Novak, RM, McElrath, MJ, Kalams, S, Keefer, M, Frahm, NA, Janes, HE, Gilbert, PB, & Tomaras, GD. (2018, March). Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial. The Journal of infectious diseases, 217 (8), 1280-1288.
Mayer, KH, Seaton, KE, Huang, Y, Grunenberg, N, Isaacs, A, Allen, M, Ledgerwood, JE, Frank, I, Sobieszczyk, ME, Baden, LR, Rodriguez, B, Van Tieu, H, Tomaras, GD, Deal, A, Goodman, D, Bailer, RT, Ferrari, G, Jensen, R, Hural, J, Graham, BS, Mascola, JR, Corey, L, Montefiori, DC, HVTN 104 Protocol Team, , & and the NIAID HIV Vaccine Trials Network, . (2017, November 14). Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial. PLoS medicine, 14 (11), e1002435-.

View All Publications